Jagsonpal Pharmaceuticals Reports Strong Q1 FY27 Results; Revenue Up 9% as Company Enters Hospital Supplies Segment via Aequitas Acquisition

Jagsonpal Pharmaceuticals Reports Strong Q1 FY27 Results; Revenue Up 9% as Company Enters Hospital Supplies Segment via Aequitas Acquisition​

Gurugram, July 29, 2026: Jagsonpal Pharmaceuticals Limited today announced its unaudited financial results for the quarter ended June 30, 2026. The company reported robust growth across key performance indicators, including a 9% year-on-year (YoY) increase in revenue and a 22% rise in Profit After Tax (PAT).

The results reflect strong operating momentum, supported by the strategic acquisition of Aequitas Healthcare, which marks Jagsonpal's entry into the hospital supplies sector. The company reported ending Q1 FY27 with cash reserves standing at ₹1,700 Mn.

Financial Performance Highlights​

Jagsonpal Pharmaceuticals delivered significant gains in profitability and operational efficiency during the quarter. Operating EBITDA rose sharply, while PAT demonstrated sustained growth across periods.

Key financial metrics for Jagsonpal Pharmaceuticals are summarized below:

Strategic Expansion and Operational Excellence​

The company reported that its operating EBITDA rose to ₹191 Mn, leading to an expansion of the EBITDA margin to 23.2%, a rise of 241 basis points (bps) YoY. Net Profit increased to ₹132 Mn, with margins expanding by 176 bps YoY to reach 16.0%.

Jagsonpal Pharmaceuticals completed the acquisition of a controlling stake (85%) in Aequitas Healthcare, immediately expanding its portfolio into hospital supplies. The company also concluded a ₹40 crore share buyback, which resulted in a ROCE improvement by 340 bps.

Manish Gupta, Managing Director and CEO of Jagsonpal Pharmaceuticals Limited, commented on the performance: "Q1 FY27 reflects sustained traction in our business, with revenue growing 9% YoY... This translated into strong financial performance, with Op. EBITDA rising 21% YoY to ₹19 crore, Op. EBITDA margin expanding 241 bps to 23.2%, and PAT growing 22%. Even with these capital allocation initiatives, we ended the quarter with a healthy cash balance of ₹170 crore."

Gupta also noted that the company significantly outperformed industry benchmarks, stating that while Pharmarack reported 18.9% growth for Jagsonpal versus 11.6% for the IPM, this move resulted in a four ranks improvement to #88 in the Indian pharmaceutical market.

Financial Stability and Market Position​

The financial snapshot shows strong liquidity management, with cash and equivalents reaching ₹1,700 Mn despite undertaking capital allocation initiatives like the buyback.

The company's key performance areas include:

• Revenue: Q1 revenue was reported at ₹822 Mn, showing a 9% YoY growth.
• Cash Position: The robust cash balance supports inorganic initiatives and demonstrates strong business hygiene.
• Market Reach: Jagsonpal maintains a pan-India presence through over 1,000 medical representatives across its portfolio, which includes key segments like Gynecology (ranked 7th as per CMARC RPM), Orthopedics (2nd as per CMARC RPM), and Dermatology.

Aequitas Integration Outlook​

The acquisition of Aequitas Healthcare, a pan-India hospital platform with over 1,000 relationships, is aimed at accelerating Jagsonpal's transition into a leading specialty pharmaceutical company.

The company has set ambitious targets for the combined entity:

• Targeted EBITDA: Jagsonpal is targeting approximately ₹10 Cr EBITDA from Aequitas by Year 2 post-integration.
• Strategic Synergy: The integration focuses on cross-selling the JPL portfolio across the newly acquired hospital network and leveraging institutional tender opportunities, which would organically take several years to build.

The company's financial standing is further detailed in the balance sheet data provided for Q1 FY27:

JAGSNPHARM Stock Price Movement​

Today, shares of Jagsonpal Pharmaceuticals Limited edged higher to close at ₹230.5, settling up 2.20% during trading. The stock saw a total traded volume of 77,095 shares throughout the session.